Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy

European Journal of Neurology

Volumn 6, Issue SUPPL. 4, 1999, Pages s23-s35

  Boyd, Roslyn N ^a   Graham, H Kerr ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Botulinum toxin type A; Cerebral palsy; Children; Physiotherapy; Spasticity

Indexed keywords

BOTULINUM TOXIN A;

CASE REPORT; CEREBRAL PALSY; CLINICAL PROTOCOL; CONFERENCE PAPER; DISEASE SEVERITY; FEMALE; GAIT; GAIT DISORDER; HUMAN; JOINT FUNCTION; MALE; MOTOR PERFORMANCE; MUSCLE LENGTH; PATIENT SELECTION; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0033382079     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1999.tb00031.x     Document Type: Conference Paper

References (39)

1. Baillieu C, Barwood S, Boyd RN, Graham HK (1997). The analgesic effects of botulinum toxin A in adductor release surgery in children with cerebral palsy: a pilot study [abstract]. Dev Med Child Neurol 39 (suppl 75):D12 (full paper in press Dev Med Child Neurol).
2. Biglan AW, Gonnering R, Lockhart LB, Rabin B, Fuerste FH (1986). Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol 101:232-235.
3. Bohannon RW, Smith MB (1987). Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206-207.
4. Boyce W, Gowland C, Hardy S, Rosenbaum P, Lane M, Plews N, et al. (1994) Development of a quality of movement measure for children with cerebral palsy. Phys Ther 71:820-832.
5. Boyd RN, Graham HK (1997). Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 4 (suppl 2): 15-22.
6. Boyd RN, Pliatsios V, Starr R, Nattrass G, Graham HK (1997). Biomechanical transformation of the gastrosoleus muscle by injection of botulinum toxin A and casting in ambulant children with cerebral palsy. American Academy of Cerebral Palsy Portland (AACPDM) [abstract]. Dev Med Child Neurol 39 (suppl 75):D13 (full paper in press Dev Med Child Neurol).
7. Boyd RN, Barwood SA, Ballieu C, Graham HK (1998a). Validity of a clinical measure of spasticity in children with cerebral palsy in a double-blinded randomised controlled clinical trial. American Academy of Cerebral Palsy Portland (AACPDM) [abstract]. Dev Med Child Neurol 40 (suppl 78):7.
8. Boyd RN, Pliatsios V, Graham HK (1998b). Use of objective measures in predicting response to botulinum toxin A in children with cerebral palsy. American Academy of Cerebral Palsy Portland (AACPDM), San Antonio. Dev Med Child Neurol 40 (suppl 78):48. (full paper in press Dev Med Child Neurol).
9. Boyd RN, Graham HK, Scott O (1999a). Botulinum toxin A and muscle contracture in ambulant children with cerebral palsy a kinematic study. MSc (Physiotherapy) thesis. London, UK: University of East London.
10. Boyd RN, Graham JEA, Nattrass GR, Graham HK (1999b). Medium-term outcome - response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol 6 (suppl 4):37-45.
11. Bower E, McLellan D (1994). Measuring motor goals in children with cerebral palsy. Clin Rehab 8:198-206.
12. Corry IS (1995). Use of a motion analysis laboratory in assessing the effects of botulinum toxin a in cerebral palsy. Thesis for Doctor of Medicine in the Faculty of Medicine. Belfast, N. Ireland: The Queens University.
13. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK (1997). Botulinum toxin A in the hemiplegic upper limb: a double blind trial. Dev Med Child Neurol 39:185-193.
14. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Eames N, Taylor TC, Graham HK (1998). Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Paediatr Orthopaedics 18:304-311.
15. Cosgrove AP, Corry IS, Graham HK (1994). Botulinum toxin in the management of the lower limb in cerebral palsy. Der Med Child Neurol 36:386-396.
16. Damiano DL, Abel MF (1996). Relation of gait analysis to gross motor function in cerebral palsy. Dev Med Child Neurol 38:389-396.
17. Davis RB III, Ounpuu S, Tyburski D, Gage J (1991). A gait analysis data collection and reduction technique. Human Movement Sci 10:575-587.
18. Eames NWA, Baker R, Hill A, Graham HK, Cosgrove AP (1999). The effect of Botulinum Toxin A on gastrocnemius muscle length: magnitude & duration of response. Dev Med Child Neurol 41:226-232.
19. Feldman AB, Hayley SM, Coryell J (1991). Concurrent and construct validity of the Paediatric Evaluation of Disability Inventory (PEDI). Phys Ther 70:602-610.
20. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E (1993). Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto-Laryngol 113: 400-404.
21. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997). Botulinum A toxin therapy: neutralizing and nonneutralizing anitbodies - therapeutic consequences. Exp Neurol 147:96-102.
22. Graham HK, Aoki R, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. (1999). Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture (in press).
23. Held JP, Pierrot-Deseilligny E (1969). Reeducation motrice des Affections Neurologiques. : JB Baillere et fils, Paris, pp. 31-42.
24. Hisslop TG (1995). Montgomery J. Daniel's and Worthingham's Muscle testing: Techniques of Manual Examination. Philadelphia: WB Saunders.
25. Kirschner J, Heinan F, Mall V, Linder M, Stein S, Michaelis U (1998). Gross Motor Function Measure for therapy evaluation in children treated with BTX-A [Abstract]. Dev Med Child Neurol 40 (suppl 78):28.
26. Koman LA, Mooney JF III, Smith BP, Goodman A (1993). Management of cerebral palsy with botulinum toxin A: preliminary investigation. J Pediatr Orthopaedics 13:489-495.
27. Koman LA, Mooney JF III, Smith BP, Goodman A (1994). Management of cerebral palsy with Botulinum toxin A: report of a preliminary randomized, double-blind trial. J Pediatr Orthopaedics 14:229-303.
28. Love SC, Blair E, Valentine JR, Chauvel J (1999). The effect of botulinum toxin on the functional ability of the child with spastic hemiplegia - a randomised controlled trial. Proceedings of the Australasian Rehabilitation meeting, Adelaide, May.
29. Msall ME, Digaudio K, Duffy LC, La Forrest S, Catanzaro NL, Campbell J, et al. (1994). The Functional Independence Measure for children (WeeFIM): conceptual basis and pilot use in children with developmental disabilities. Clin Pediatr 33:421-430.
30. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B (1997). Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39:214-223.
31. Perry J (1974). Kinesiology of lower extremity bracing. Clin Orthopaedics Related Res 102:20-31.
32. Resales RL, Arimura K, Takenaga S, Osame M (1996). Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve 19:488-496.
33. Russell, D, Rosenbaum, P, Gowland, C, Hardy S, Lane M, Plews N, et al. (1993). The Gross Motor Function Measure 2nd edition. Toronto,Canada: Hugh McMillan Rehabilitation Centre, McMaster University.
34. Saltiel J (1969). A one-piece, laminated, knee locking, short leg brace. Bull Orthotics Prosthetics 23:68-75.
35. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG (1996). Injection of botulinum toxin A into the gastrocnemius muscle of patients with cerebral palsy: a 3 dimensional motion analysis study. Gait Posture 4:269-279.
36. Sutherland DH, Kaufman KR, Wyatt MD, Chambers HG, Mubarak SJ (1999). Double-blind study of Botulinum Toxin type A injections into the gastrocnemius muscle in patients with Cerebral Palsy. Gait Posture 10:1-9.
37. Tardieu G, Shentoub S, Delarue R (1954). A la recherche d'une technique de mesure de la spasticite. Rev Neurol 91:143-144.
38. Wiley ME, Damiano DL (1998). Lower extremity strength profiles in spastic cerebral palsy. Dev Med Child Neurol 40:100-107.
39. Winters TF, Gage JR, Hicks R (1987) Gait patterns in spastic hemiplegia in children and adults. J Bone Joint Surgery (Am) 69:437-441.